A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
about
Building a 3D Virtual Liver: Methods for Simulating Blood Flow and Hepatic Clearance on 3D StructuresDevelopment of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly IndividualsPhysiologically based pharmacokinetic modeling framework for quantitative prediction of an herb-drug interaction.Relevance of Liver Failure for Anti-Infective Agents: From Pharmacokinetic Alterations to Dosage AdjustmentsExpression of P450 and nuclear receptors in normal and end-stage Chinese livers.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.Application of a physiologically based pharmacokinetic model informed by a top-down approach for the prediction of pharmacokinetics in chronic kidney disease patients.Physiologically based pharmacokinetic modeling: methodology, applications, and limitations with a focus on its role in pediatric drug development.The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development.Human Ontogeny of Drug Transporters: Review and Recommendations of the Pediatric Transporter Working GroupPharmacokinetic/Pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors.A physiologically based pharmacokinetic drug-disease model to predict carvedilol exposure in adult and paediatric heart failure patients by incorporating pathophysiological changes in hepatic and renal blood flowsDevelopment of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.Pharmacokinetics of the New Hepatitis C Virus NS3 Protease Inhibitor Narlaprevir following Single-Dose Use with or without Ritonavir in Patients with Liver Cirrhosis.Quantitative structure-pharmacokinetic relationships.Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.Physiologically based pharmacokinetic (PBPK) modelling tools: how to fit with our needs?Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology.Individualization of drug therapy: history, present state, and opportunities for the future.Predicting drug-drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach.Approaches for dosage individualisation in critically ill patients.Pharmacokinetic of antiepileptic drugs in patients with hepatic or renal impairment.Some considerations on the predictions of pharmacokinetic alterations in subjects with liver disease.Physiologically based pharmacokinetic modeling in drug discovery and development: a pharmaceutical industry perspective.Asunaprevir: A Review of Preclinical and Clinical Pharmacokinetics and Drug-Drug Interactions.Physiologically Based Pharmacokinetic (Pbpk) Model of the Cyp2d6 Probe Atomoxetine: Extrapolation to Special Populations and Drug-Drug Interactions.Physiologically Based Pharmacokinetic Modelling and Prediction of Metformin Pharmacokinetics in Renal/Hepatic-Impaired Young Adults and Elderly Populations.Role of Quantitative Clinical Pharmacology in Pediatric Approval and Labeling.Transporter Expression in Liver Tissue from Subjects with Alcoholic or Hepatitis C Cirrhosis Quantified by Targeted Quantitative ProteomicsDrug metabolism and liver disease: a drug-gene-environment interaction.Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.Physiologically Based Pharmacokinetic Modeling of Palbociclib.Optimizing the Clinical Use of Carvedilol in Liver Cirrhosis Using a Physiologically Based Pharmacokinetic Modeling Approach.Application of PBPK modelling in drug discovery and development at Pfizer.Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.Physiologically Based Pharmacokinetic Modeling for Predicting the Effect of Intrinsic and Extrinsic Factors on Darunavir or Lopinavir Exposure Coadministered With Ritonavir.Elucidating the Plasma and Liver Pharmacokinetics of Simeprevir in Special Populations Using Physiologically Based Pharmacokinetic Modelling.Organ Impairment-Drug-Drug Interaction Database: A Tool for Evaluating the Impact of Renal or Hepatic Impairment and Pharmacologic Inhibition on the Systemic Exposure of Drugs.
P2860
Q28554261-5865C07E-D3B4-4D05-9889-D9270F1F68B6Q30828459-DEE16B67-44E8-400F-923F-7669CF1FFDBCQ33702513-1E1F58F6-F9E2-4270-805C-593FFFA030EBQ33763177-10629814-26E6-4730-9096-466AD770D32BQ33887136-8E67B296-5BA5-4753-BE31-9AB7ECBF2391Q34075909-472B804E-CD01-49B0-9C59-1CF64965D523Q34099766-E5F0A236-21DB-472C-8C41-CA34EA25EDBFQ35054518-CC19757A-A3BA-42E2-9238-349EC15A6B46Q35560052-2245D15F-7D43-4DF1-80C6-A6CB8EC7AE14Q35667919-4D4804F4-A59C-4F94-89DB-C027CA543D3DQ36018848-532C9F7C-B7AB-4DEE-B450-7FFF5FA9DAE0Q36025902-C3BA13A6-29B7-4F79-8F2B-C21081D0BED2Q36806598-9CD87C64-3540-4E2F-A2FD-82F554BAC2D9Q36910606-D1AF4D6F-0B5F-4655-B44B-BAA0E458F96AQ37317619-A621827B-1E5F-4A67-B8DA-825135DEF987Q37428608-74B08610-78BC-4EAE-B533-16AFD486CEB9Q37812139-B04D7B5B-63A8-4497-A9A4-F1E4A7B51C0BQ37824590-5E048DD2-77B2-4EE9-AF7D-742547134D53Q37974113-DF567A27-5A68-4282-8649-E922C8B1AFFEQ38014312-5FF5C799-D45F-46CE-A753-D98ED0EDCFF9Q38040697-055A5AEB-758C-4907-BE87-B77E1A01B875Q38087695-38649692-A4A5-43C7-981E-F1DA4E7432C0Q38125209-1582D039-56C4-42E1-AE28-CC00798D446CQ38152329-F84E1B08-3260-4E79-8A64-0CA4D1C461E4Q38248974-9549FA1A-8A15-4FB1-B8B8-771FB4745231Q38351385-FEA70987-068D-4A76-96C7-E628927AAF93Q38547705-A91DC65F-3C47-4B3E-84FD-911DEA6D041BQ38599220-0843FA19-4643-4940-B796-8D4551267188Q38768114-4F09ACEC-CD5B-41FC-AFD1-9626E93A2CF5Q38808391-FBC406AD-EF94-4A93-A049-67DDEFE12975Q38829596-6F62D618-E745-4749-A422-8A78345FDEA2Q39037269-793AD956-9449-4E1B-8796-2100C35B161AQ39183375-BFAEFE67-21E4-4498-9ED1-4DE7735383DDQ39612151-A2ABBAD3-FD64-4E39-B58B-7C71CFBFA5ABQ39676474-18124D67-5F46-4DF5-B947-20553366E553Q39692575-EC8A2755-8348-44BE-9A44-1B4FD6F7384FQ39870288-5F652548-9564-4333-82B7-170A9C433FE3Q40189483-ED8788C9-E420-4656-90BE-0329D5B2651AQ40431727-AD115EF5-54AB-4949-9DA7-83552934B651Q40529265-F9673E16-FEE4-44BB-A2D9-216FED6D20A0
P2860
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@ast
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@en
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@nl
type
label
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@ast
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@en
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@nl
prefLabel
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@ast
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@en
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@nl
P2093
P2860
P1476
A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance.
@en
P2093
Amin Rostami-Hodjegan
Geoffrey T Tucker
Karen Rowland-Yeo
Koen Boussery
Trevor N Johnson
P2860
P304
P356
10.2165/11318160-000000000-00000
P577
2010-03-01T00:00:00Z
P6179
1021670672